Enveric Biosciences reports new data on EB-003 receptor signaling Feb 19, 2026 08:01AM
Enveric licenses RCANN trademark portfolio to TOTEC Pharma Jan 29, 2026 08:05AM
Enveric Biosciences receives US patent for neuroplastogenic molecules Dec 29, 2025 08:00AM
Enveric Biosciences raises $3.1 million from warrant exercises Dec 12, 2025 04:46PM
Enveric Biosciences raises $3.1 million through warrant exercise Dec 11, 2025 01:43PM


Nov 14, 2025 05:44PM Enveric Biosciences Inc. (ENVB) Misses Q3 EPS by 1081c
Oct 16, 2025 08:32AM Enveric Biosciences receives 23rd U.S. patent for neuroplastogen compounds
Oct 15, 2025 08:01AM Enveric hires Fish and Richardson to defend patent amid AbbVie deal
Oct 14, 2025 09:02AM Enveric Biosciences explores digital asset treasury strategy
Oct 2, 2025 08:45AM Enveric completes manufacturing milestones for EB-003 drug candidate
Sep 29, 2025 04:33PM Enveric Biosciences Inc. (ENVB) files for 5.02M share offering by selling stockholders
Sep 18, 2025 04:30PM Enveric Biosciences raises $2.2 million through warrant exercise
Sep 17, 2025 09:24AM Enveric Biosciences raises $2.2 million through warrant exercise
Sep 16, 2025 08:45AM Enveric Biosciences plans early 2026 IND filing for EB-003 after FDA feedback
Jul 23, 2025 08:03AM Enveric Biosciences receives second US patent for mescaline derivatives
Jul 15, 2025 09:04AM Enveric Biosciences drug candidate shows promise in PTSD study
Jun 24, 2025 09:03AM Enveric Biosciences Inc. (ENVB) Announces Data that Broadens Scope of Clinical Indication Potential for EB-003
Jun 10, 2025 09:03AM Enveric Biosciences (ENVB) Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
Jun 3, 2025 09:01AM Enveric Biosciences Inc. (ENVB) Issued U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
May 28, 2025 09:03AM Enveric Biosciences (ENVB) Reports Positive Preclinical Results for EB-003
May 20, 2025 08:06AM Enveric Biosciences Inc. (ENVB) Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
May 14, 2025 06:37PM Enveric Biosciences, Inc. (ENVB) Misses Q1 EPS by 82c
Apr 10, 2025 06:26AM Enveric Biosciences Inc. (ENVB) Files $200M Mixed Shelf
Mar 6, 2025 10:00AM Enveric Biosciences Inc. (ENVB) Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
Feb 27, 2025 09:30AM Enveric Biosciences (ENVB) CEO Issues Letter to Shareholders
Feb 25, 2025 01:30PM Enveric Biosciences (ENVB) Unveils EVM401 Series of Compounds with New U.S. Patent
Jan 30, 2025 04:03PM Enveric Biosciences (ENVB) Receives Notice of Allowance for EB-003
Dec 2, 2024 08:03AM Enveric Biosciences Inc. (ENVB) Announces New U.S. Patents Supporting EVM301 and EVM201
Nov 15, 2024 06:17AM Enveric Biosciences, Inc. (ENVB) Tops Q3 EPS by 28c
Nov 12, 2024 09:02AM Enveric Biosciences (ENVB) Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Nov 4, 2024 09:00AM Enveric Biosciences (ENVB) Announces Broad Range of Patent Issuances
Aug 13, 2024 08:01AM Enveric Biosciences Inc. (ENVB) and Aries Science & Technology Receive Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
Aug 13, 2024 07:00AM Enveric Biosciences, Inc. (ENVB) Tops Q2 EPS by 24c
Jul 25, 2024 08:03AM Enveric Biosciences (ENVB) Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
Jul 15, 2024 09:03AM Enveric Biosciences (ENVB) and Aries Science Enter Licensing Agreement
Jul 10, 2024 08:00AM Enveric Biosciences (ENVB) Announces Patent Granted for Drug Candidate
Jul 8, 2024 05:13PM Enveric Biosciences Inc. (ENVB) Files $200M Mixed Shelf
Jun 25, 2024 08:03AM Enveric Biosciences (ENVB) Provides Strategic Outlook and Pipeline Update